Through chemical modification and various methods, different nucleic acid drugs can be combined to create a composite drug for co-delivery. This approach can enhance therapeutic efficacy while minimizing the toxic side effects associated with the drugs. CD Formulation is dedicated to delivering advanced co-delivery solutions for nucleic acid drugs to the scientific research and pharmaceutical sectors.
Fig.1 Nucleic Acid Drug Co-Delivery. (CD Formulation)
Methods | Advantages |
---|---|
Co-delivery of Antisense DNA and siRNA | The advantages of various vectors can be fully utilized. For instance, viral vectors offer efficient transfection, while liposomes provide excellent stability and delivery. |
Co-delivery of Antisense DNA and CRISPR/Cas9 | The combination of antisense DNA and CRISPR/Cas9 enables more precise, multi-level gene regulation and enhances therapeutic efficacy. |
Co-delivery of Antisense DNA and DNAzyme | The combination of antisense DNA and DNAzyme can simultaneously enhance gene inhibition efficiency by blocking the translation of target mRNA and cleaving specific RNA sequences. |
The key to carrier design and optimization solutions lies in enhancing biocompatibility, stability, and targeting. Through chemical modification and surface functionalization, carriers can be improved for cell membrane penetration, reduced in particle size to enhance in vivo circulation time, and increased in surface ligands for specific cell or tissue recognition and targeted delivery. Additionally, these modifications can achieve synergistic therapeutic effects by loading multiple functional nucleic acid drugs.
Co-delivery of nucleic acid drugs involves chemical modifications to enhance their stability, bioavailability, and intracellular transport efficiency. During the design process, protective groups can be utilized to shield the nucleic acid drug from degradation, while modifications such as PEGylation and lipid incorporation can be introduced to improve blood circulation time and facilitate cell membrane penetration.
The development of delivery routes scientifically designs and optimizes the administration methods for nucleic acid drugs (e.g., intravenous injection, local injection, inhalation, etc.). This process is combined with the use of precise delivery systems to ensure that nucleic acid drugs can efficiently enter target cells or tissues and exert their effects.
Technology: Polymeric vehicles technology for nucleic acid co-delivery
Journal: Advanced drug delivery reviews
IF: 17.873
Published: 2020
Results:
Polymeric vectors are versatile tools for therapeutic gene delivery. Design schemes for polymer synthesis yield a variety of molecules and resulting vector formulations. Depending on the application, these properties can be adapted to enhance binding to nucleic acid cargoes and cells and to improve endosomal escape or sustained transport. Here, the authors will describe current methods and related strategies for using polymers for gene delivery in preclinical and clinical applications. Polymeric vectors for the delivery of genetic material have achieved significant therapeutic endpoints in vitro and in animal models.
Fig.2 Polymeric vehicles for nucleic acid co-delivery. (Piotrowski-Daspit A S, et al., 2020)
CD Formulation's nucleic acid drug co-delivery solutions ensure the stable and efficient delivery of nucleic acid drugs in vivo. By utilizing advanced carrier technology, we significantly enhance drug bioavailability and therapeutic efficacy. Contact us for a customized solution.
References